Shingles News

The Centers for Disease Control and the Olmsted Medical Center Research Department have a new shingles study.

Thank you for your question! It will be reviewed and considered for posting on CNNHealth.com. Questions and comments are moderated by CNN and will not appear until after they have been reviewed and approved.

Preventative measures at any age can help avoid potentially serious problems. Content courtesy of the American Geriatrics Society December 14, 2009 Research shows that there are two major factors that impact aging - those caused by the genes we inherit and those changes caused by environmental factors, such as exposure to the sun's rays, illness or ...

Dr. James Steckelberg is chairman of the Division of Infectious Diseases at Mayo Clinic, a consultant and a professor of medicine at Mayo Medical School.

Nearly one in three Canadians will develop shingles in their lifetime. Pain together with a rash are the red flags doctors say shouldn't be ignored.

The pain remaining after an acute episode of shingles is called postherpetic neuralgia .

EPB-348 is a potent inhibitor of herpes viruses, including the varicella zoster and Epstein-Barr viruses licensed from the Swedish biotech company Medivir AB.

Main Category: Infectious Diseases / Bacteria / Viruses Also Included In: Dermatology Neurology / Neuroscience The US Food and Drug Administration announced yesterday that it has approved Qutenza 8% patch for the treatment of post-herpetic neuralgia , an often excruciating pain that can persist for weeks, months and even years in 10 to 15 per cent ...

Epiphany Biosciences announced results from its Phase 2b dose-ranging study of EPB-348 in patients with shingles infection.

The Qutenza skin patch has been approved by the U.S. Food and Drug Administration to treat pain due to postherpetic neuralgia , the nerve pain that may follow shingles, drug maker NeurogesX said in a news release.

NeurogesX Inc. won approval for its Qutenza patch to treat shingles-related pain.

Shingles, also known as herpes zoster, is the skin rash as a result of a virus.A This virus, Varicella zoster virus, is also the same virus that causes chickenpox.A When a person contracts chickenpox and it has cleared it does not fully go away, but stays within you.

Get the latest news alerts: Follow LTW at Twitter. Local Tech Wire RESEARCH TRIANGLE PARK, N.C. The U.S. Food and Drug Administration has pushed back its delay of a proposed treatment for shingles that is being developed by GlaxoSmithKline and California-based XenoPort.

You are seeing this message because your Web browser does not support basic Web standards.

To read this article in full you must have registered and have a Premium Content Subscription with the NHS Choices site.

The recent vaccine developed for the treatment of Shingles, can it be used against HSV-1 and HSV-2? 10/14/09 MOJO Topics: Vaccine for HSV-1 and HSV-2 The recent vaccine developed for the treatment of Shingles the herpes Zoster infection for people 65 and older, can that very same vaccine be used for the prevention of recurrent attacks of HSV-1 ...

Full-time university students are guaranteed unlimited visits to the student health center, but medication purchases depend on prescription card plans.

Each year more than one million people in the U.S. suffer an outbreak of shingles, a blistering rash caused by the same virus that causes chickenpox.

Adults with shingles were about 30 percent more likely to have a stroke during a one-year follow-up than adults without shingles.

Earlier this week, a new report from Taiwanese researchers in the journal Stroke noted that adults who had had herpes zoster were 31% more likely to suffer a stroke within a year than were people who had not had shingles.